Notably, as BRAF mutant thyroid cancers are generally known for their insensitivity to RAI therapy [39] and SH treatment resulted in a 1.747-fold increase in iodine uptake by the BRAF mutant cell line BCPAP (4 mM SH), this further strengthens the clinical potential of SH in restoring RAI sensitivity, even in poorly differentiated thyroid cancers. This evidence concerns the gene BRAF and thyroid cancer.